skip to main content

HER2 Endometrial Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersHER2 Endometrial CancerSCE Medical Oncology

A patient has recurrent mismatch-repair-proficient endometrial carcinoma progressing during carboplatin–paclitaxel. Pelvic MDT review concludes neither surgery nor radiotherapy can be curative. Which NHS systemic option is supported by NICE TA904?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CUse pembrolizumab plus lenvatinib after progression on or after platinum treatment

TA904 recommends pembrolizumab plus lenvatinib for advanced or recurrent endometrial cancer that has progressed on or after platinum chemotherapy when curative surgery or radiotherapy is not possible. The recommendation is not monotherapy and does not mandate two extra regimens; a curative local option would take the patient outside the appraisal population.

Reference: NICE TA904: pembrolizumab with lenvatinib for advanced endometrial cancer. https://www.nice.org.uk/guidance/ta904/chapter/1-Recommendations